Statement

Sl.No.	Name of Drug	Price/Kg, (Rs.) After revision (Rs.) Kg,	Before revision (Rs.) Kg.	Present Price (Rs.) Kg.
1	Phenytoin Sodium	236·00 (23-1-1991)	261·06 (26-8-1976)	236·00 (23-1-1991)
2	Metronidazole	428·00 (1-2-1991)	482·00 (9-9-1988)	475·00 (14-6-1991)
3	Metronidazole Benzoate	380·00 (1-2-1991)	511·00 (25-1-1985)	456·00 (1 4-8-1991)
4	Ibuprofen	450·00 (1-2-1991)	502·00 (27-6-1989)	521·00 (30-8-1991)
5	Amoxycillin Trihydrate	2093·00 (11-2-1991)	2660·00 (21-3-1989)	2649·00 (14-10-1991)
6	Analgin	251·00 (26-2-1991)	280·00 (1-6-1990)	296·00 (25-9-1991)
7	Sulphacetamide	350·00 (7-3-1991)	352·00 (20-6-1989)	350·00 (7-3-1991)
8	Sulphamethoxazole	340·00 (7-3-1991)	390·00 (20-6-1990)	351·00 (25-9-1991)
9	Methyldopa	1967·00 (7-3-1991)	2148·00 (20-1-1986)	2434·00 (30-8-1991)
10	Isoxuprine	6401·00 (7-3-1991)	8997·00 (14-9-1984)	7442·00 (1-11-1991)
11	Sulphamoxole	399·00 (3-6-1991)	430·00 (11-10-1981)	466·00 (30-8-1991)

Liabilities of Drug Companies

670. SHRI R. S. NAIK.
SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answer to the Unstarred Question 1655 given in the Rajya Sabha on the 12th Sepember, 1991 and state:

(a) what are the details of liabilities of each company involved in the court case as assessed upto 31st October, 1991 and what are the amounts deposited by each into the DPEA so far;

(b) whether it is a fact that there are hinderances in the recovery of amount assessed in each case;

(c) if So, what are the details of the same and what steps have been taken to-remove the hinderances;

(d) whether it is a fact that Government have still to assess the amount on certain drugs involved in court case;

(e) if so, names of the drugs, period for which assessment is to be done and reasons for delay;

(f) whether it is also a fact that Government have not started assessment in respect of Xylocaine formulations; and

(g) if so, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Perhaps the reference is to Unstarred Question No. 1655 answered on 1st August, 1991 and not the one answered on 12th September, 1991. The details of liabilities of various companies and the amount deposited by each into the DPEA so far, are given in the Annexure: (See Appendix CLXL, Annexure No. 131).

(b) to (e) A number of companies were asked to discharge their entire liability failing which the Government will be constrained to process action for recovery of the amount as arrears of land revenue along with the interest from the date of default. A few of them have however, filed writ petition and obtained stay ordsrs from the High Courts. Some of them have also asked for personal bearing and they are being heard.

(f) and (g) The matter is being looked into.

Position of DPSC

671. SHRI R. S. NAIK:
SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1665 given in the Rajya Sabha en 12th September, 1991 and state:

(a) what is the position of DPRc Sub-Committee whieh works out the prices of formulations of drugs;

(b) whether DPRC belongs to BICP or is it an interministerial committee;

(c) who is the Chairman of the committee and to which organisation he belongs and what are the names of organisations to which each member of DPRC belongs;

(d) whether it is a fact that Chairman of the DPRC refused to consider the prices of formulations reduction based on notified reduced prices; and

(e) if so, names of the drugs whose prices were reduced during this year and the committee did not work for the reduction of formulation prices?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) DPRC Sub-Committee recommends the prices of drug formulations to the Government under DPCO, 1987 in accordance with a formula and fixed norms.

It is an Inter-Minsterial Committee.

(c) Member Finance, BICP is the Chairman of the DPRC Sub-Committee with members from the Department of Chemicals and Petrochemicals, Director General of Health Services (DGHS) and Directorate General of Technical Development (DGTD).

(d) and (e) The BICP had some difference of opinion as to the reduction in the prices of bulk drugs which was sorted out later. However, the scenario has changed after the exchange rate adjustment announced by the Government. As a result, prices of 9 out of 11 bulk drugs whose prices were reduced, have been revised upwards. In 4 cases, the revised prices are even more than the prerevised prices. The exercise to notify the prices of ceiling packs of formulations where the bulk drug price is still less than the pre reduced price is on hand.

'Collecting data of drug Companies

672. SHRI R. S. NAIK;

SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1654 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what are the names of companies which BICP addressed to collect date for study of conversion cost and packing charges;

(b) whether it is a fact that the copy of the communication was endorsed to Government;